drugset / Trial / NCT06124794
The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT\_BTA\_P3\_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after administration of clinical trial drugs, and evaluates the effectiveness and safety of repeated administration of protoxin in those with moderate or severe brow wrinkles.
Timeline
- Start
- 2023-12-18
- Primary completion
- 2024-02-26
- Completion
- 2024-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PROTOXIN | Protein / enzyme biologic | 20 iu | Other |
Indications
No indication recorded.